Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
Site Search
Showing 1 - 4 of 4 results
Press Release
|
June 13, 2021
|
4 min read
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
Press Release
|
Jan. 4, 2022
|
4 min read
Observational study supported by the CF Foundation will monitor real-world experience with Trikafta
Press Release
|
June 2, 2021
|
4 min read
The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.
Press Release
|
April 3, 2024
|
3 min read